JAK1 (JH2 Pseudokinase Domain) Inhibitor Screening Assay Kit
The JAK1 (JH2 Pseudokinase Domain) Inhibitor Screening Assay Kit is a fluorescence polarization-based assay designed for screening and profiling small molecules that displace the fluorescently labeled probe (JH2 probe 1) from the JAK1 (Janus kinase 1) JH2 Pseudokinase Domain. This kit comes in a convenient 384-well format, with enough recombinant human JAK1 (JH2 Pseudokinase Domain), buffer, and fluorescently labeled JH2 Probe 1 for 384 reactions.
Figure 1: Illustration of the assay principle.
The assay is based on the competition between a test compound and the JH2 probe for the purified JAK1 (JH2 Pseudokinase Domain). JH2 Probe 1 is incubated with JAK1 (JH2 Pseudokinase Domain) in the presence or absence of an inhibitor. When the JH2 Probe 1 is bound to the JH2 Pseudokinase Domain it has high FP due to its restricted movement. A competitive inhibitor prevents the probe from binding to the JH2 Pseudokinase Domain, therefore most of the probe is in free form and has low FP (fluorescence polarization). Compared to a control without inhibitor, FP decreases proportionally to the inhibitor concentration.
This assay requires a fluorescent microplate reader capable of measuring fluorescence polarization (FP) to read the FP signal. For more information FP technology, visit our Tech Note: FP, assay principles and applications.
- Microplate reader capable of reading fluorescence polarization
- Adjustable micropipettor and sterile tips
- Rotating or rocker platform
| Catalog # | Name | Amount | Storage |
| 101946 | JAK1 (JH2 Pseudokinase Domain), His-Tag* | 40 µg | -80°C |
| 78103 | 10 µM JH2 Probe 1 (Protect from light) | 10 µl | -80°C |
| 78106 | JH2 Binding Buffer | 25 ml | -20°C |
| 79961 | 384-well microplate, black | 1 plate | Room Temp |
*The concentration of the protein is lot-specific and will be indicated on the tube.
Janus kinases (JAKs) are a family of intracellular non-receptor tyrosine kinases, including JAK1, JAK2, JAK3 and TYK2 (tyrosine kinase 2), important in the modulation of inflammatory processes. JAKs contain a catalytically inactive pseudokinase regulatory domain (JH2), that acts as a negative regulator, as well as an active kinase domain (JH1). Most of the mutations in JAK proteins that link to hematological and immune-related diseases occur in the JH2 domain, resulting in increased JAK2 activity or decreased cytokine-induced signaling. Most inhibitors developed so far target the JH1 domain and seem unable to fully treat the disease, while generating significant side effects by suppressing normal cytokine signaling. Recent reports demonstrate that the pseudokinase domain of JH2 could provide an ideal site for selective inhibitor development and support the treatment of diseases like myeloproliferative neoplasms (MNPs), while generating minimal side effects. The development of such inhibitors will open new avenues in cancer therapy.
Powered by Bioz
San Diego, CA 92121
858-202-1401
Products are for Research Use Only
COMPANY
Copyright © 2024
BPS Bioscience, Inc.
All rights reserved.
Diagrams on this website are created with BioRender.com.